BridgeBio Oncology Therapeutics, Inc. (BBOT) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-06

BridgeBio Oncology Therapeutics, Inc. (BBOT) has filed 17 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-06. 4 Form 8-K material event filings were reported by BBOT in the last 90 days. InsiderAlpha tracks every BBOT SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About BridgeBio Oncology Therapeutics, Inc. (BBOT)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001869105

90-Day SEC Filing Activity

Form 4 filings (90d)	17
Form 8-K filings (90d)	4
Latest Form 4 filing	2026-07-06

Recent BBOT Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-07-01	Chen Bihua	Director	J — Other acquisition / disposition	4.53M	$0.00	—	SEC
2026-07-01	Beltran Pedro	President and CEO	F — Tax withholding / forfeiture	1.0K	$7.80	$8K	SEC
2026-07-01	Ben Yong	Chief Med & Dev Officer	F — Tax withholding / forfeiture	1.0K	$7.80	$8K	SEC
2026-07-01	Elmelech Idan	COO & Principal Financial Ofcr	F — Tax withholding / forfeiture	343	$7.80	$3K	SEC
2026-07-01	Cobo Marc	Principal Accounting Officer	F — Tax withholding / forfeiture	125	$7.80	$975	SEC
2026-07-01	Chen Bihua	Director	J — Other acquisition / disposition	130.9K	$0.00	—	SEC
2026-07-01	Chen Bihua	Director	J — Other acquisition / disposition	1.70M	$0.00	—	SEC
2026-07-01	Chen Bihua	Director	J — Other acquisition / disposition	2.69M	$0.00	—	SEC
2026-04-01	Mehra Uneek	Insider	F — Tax withholding / forfeiture	524	$9.03	$5K	SEC
2026-04-01	Ben Yong	Chief Med & Dev Officer	F — Tax withholding / forfeiture	1.0K	$9.03	$9K	SEC
2026-04-01	Beltran Pedro	President and CEO	F — Tax withholding / forfeiture	1.0K	$9.03	$9K	SEC
2026-03-10	Beltran Pedro	Chief Scientific Officer	A — Grant or award	46.7K	$0.00	—	SEC
2026-03-10	Mehra Uneek	Chief Financial Officer	A — Grant or award	23.3K	$0.00	—	SEC
2026-03-10	Ben Yong	Chief Med & Dev Officer	A — Grant or award	46.7K	$0.00	—	SEC
2025-10-10	BridgeBio Pharma LLC	Insider	J — Other acquisition / disposition	784.7K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for BridgeBio Oncology Therapeutics, Inc. (BBOT). Updated in real time as new filings are submitted to the SEC.

Most-Active BBOT Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Chen Bihua	5	—
Beltran Pedro	3	$18K
Elmelech Idan	2	$3K
Ben Yong	2	$18K
MCCORMICK FRANK	1	—

Recent BBOT Form 8-K Material Events

2026-06-22 — Item 5.02, 5.07 [SEC]
2026-05-12 — Item 2.02, 9.01 [SEC]
2026-04-29 — Item 5.02 [SEC]
2026-04-22 — Item 5.02, 7.01, 9.01 · Leadership · neutral [SEC]
BridgeBio Oncology Therapeutics appointed Pedro Beltran, Ph.D. as President and Chief Executive Officer effective immediately, succeeding Eli Wallace. Dr. Beltran was previously the Company's Chief Scientific Officer and brings extensive oncology research experience from roles at
2026-03-26 — Item 5.02 · Leadership · neutral [SEC]
BridgeBio Oncology Therapeutics appointed Peter Lebowitz, M.D., Ph.D. as a new independent director on March 24, 2026, increasing the board size to nine members. Dr. Lebowitz will serve on the Nominating and Corporate Governance Committee and the Compensation Committee.

Recent Insider Filings

2026-07-06 — Cobo Marc (Principal Accounting Officer)
2026-07-06 — Elmelech Idan (COO & Principal Financial Ofcr)
2026-07-06 — Ben Yong (Chief Med & Dev Officer)
2026-07-06 — Beltran Pedro (President and CEO)
2026-07-06 — Chen Bihua (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in BBOT insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

BBOT Insider Trading — FAQ

What is the latest insider trade for BBOT?: BridgeBio Oncology Therapeutics, Inc. (BBOT) had 17 insider filings in the last 90 days, with the most recent on 2026-07-06. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying BBOT stock?: 0 insider purchases of BBOT were filed in the last 90 days.
How many insiders are selling BBOT stock?: 0 insider sales of BBOT were filed in the last 90 days.
Where can I see BBOT SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every BBOT SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live BBOT dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.